According to Zacks, “Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year.”
Zacks Investment Research lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a hold rating in a report published on Wednesday morning.
A number of other research analysts have also recently issued reports on the stock. ValuEngine cut shares of Theravance Biopharma from a buy rating to a hold rating in a research note on Tuesday, January 22nd. BidaskClub upgraded shares of Theravance Biopharma from a buy rating to a strong-buy rating in a research note on Thursday, January 10th. Finally, Cantor Fitzgerald began coverage on shares of Theravance Biopharma in a research note on Monday, January 28th. They issued a buy rating and a $55.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $43.40.
NASDAQ:TBPH opened at $24.00 on Wednesday. Theravance Biopharma has a 1 year low of $21.04 and a 1 year high of $35.48. The company has a debt-to-equity ratio of 6.52, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market capitalization of $1.27 billion, a PE ratio of -6.02 and a beta of 1.69.
In other news, SVP Sharathchandra S. Hegde sold 9,033 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total value of $223,205.43. Following the completion of the transaction, the senior vice president now owns 270,134 shares of the company’s stock, valued at approximately $6,675,011.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the company. Candriam Luxembourg S.C.A. acquired a new position in Theravance Biopharma in the 3rd quarter worth $8,321,000. BlackRock Inc. boosted its stake in Theravance Biopharma by 2.2% in the 3rd quarter. BlackRock Inc. now owns 3,833,409 shares of the biopharmaceutical company’s stock worth $125,239,000 after purchasing an additional 82,620 shares during the period. United Services Automobile Association acquired a new position in Theravance Biopharma in the 3rd quarter worth $210,000. Ibex Investors LLC acquired a new position in Theravance Biopharma in the 3rd quarter worth $1,506,000. Finally, Virtus ETF Advisers LLC boosted its stake in Theravance Biopharma by 7.2% in the 3rd quarter. Virtus ETF Advisers LLC now owns 32,226 shares of the biopharmaceutical company’s stock worth $1,053,000 after purchasing an additional 2,171 shares during the period. 84.42% of the stock is owned by institutional investors.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
Recommended Story: How is inflation measured?
Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com